Phase 4 N=10 Brain Effects of Opiate Agonist and Antagonist
Chronic Low-back Pain
Primary: Mean Change in Subcortical Brain Structure Volume — 0.054; 0.74; 0.27; 0.48 cubic centimeters — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Cryoanalgesia vs. Epidural in the Nuss Procedure
Pectus Excavatum · Funnel Chest
Primary: Length of Hospitalization — 3; 5 Length of Stay (Post-Operative Days)
Phase 4 N=102 Ibuprofen Versus Ibuprofen/Acetaminophen Postoperatively in Patients Needing Root Canal Therapy
Pain, Postoperative
Primary: Heft Parker Visual Analog Scale Pain Scale Pain Measurements — 63; 60 units on a scale
Phase 4 N=52 Tacrolimus Versus Prednisolone for the Treatment of Minimal Change Disease
Minimal Change Disease
Primary: Percentage of Participants Achieving Complete Remission From Nephrotic Syndrome at 8 Weeks — 21; 17 Participants — p=0.12
Phase 4 N=50 Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
Hemophilia A
Primary: Percentage of Participants Who Developed Factor VIII (FVIII) Inhibitors — 0 percentage of participants
Phase 4 N=6 Pilot Study for Zoledronic Acid to Prevent Bone Loss After Bariatric Surgery
Bariatric Surgery Candidate
Primary: Change in Serum CTX — 0.228 ng/ml
Phase 4 N=144 Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study
Phantom Limb Pain
Primary: "Average" Phantom Limb Pain Intensity 4 Weeks Following Initiation of an Ambulatory Continuous Peripheral Nerve Block (as Measured by the Numeric Rating Scale Within the…
Phase 4 N=157 Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose
Magnetic Resonance Imaging
Primary: Degree of Lesion Contrast Enhancement — 0.884; 0.863; 3.007; 2.979 Scores on a scale — p=< 0.0001
Phase 4 N=45 Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking
Smoking Cessation · Alcohol Drinking
Primary: Number of Participants Who Self-report Prolonged Abstinence From Smoking — 3; 0 Participants
Phase 4 N=17 Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD
Chronic Hemodialysis (ESRD)
Primary: Rate of Hypotension, Serious Adverse Events, GI Events and Cardiovascular Death — 1; 6; 5; 3 Participants — p=0.04
Phase 4 N=201 ABSORICA in Patients With Severe Recalcitrant Nodular Acne
Acne
Primary: Active Treatment Period: Total Acne-Specific Quality of Life Score at Week 20 — 100.7 score
Phase 4 N=27 Intrathecal (IT) Baclofen Drug Distribution
Muscle Spasticity
Primary: Subjects Experiencing Maximal MAS Change From Baseline - Spasticity of Cerebral Origin — 8; 7; 3; 3 Participants
Phase 4 N=53 Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
Phase 4 N=86 TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery
Colorectal Surgery · TAP Blocks
Primary: Mean Opioid Consumption in Morphine Opioid Equivalents in mg — 112.12; 97.95 IV morphine equivalents (mg)
Phase 4 N=1,002 Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event
Heart Failure With Reduced Ejection Fraction
Primary: Percentage of Patients Achieving the Target Dose of LCZ696 200 mg Bid at 10 Weeks Post Randomization — 224; 248 Participants — p=0.099